Liquid Torem Toremifene 60mL 60mgs/mL
Liquid Torem Citrate, also known as Fareston, is a Selective Estrogen Receptor Modulator (SERM) similar to Liquid Tamox Citrate (Nolvadex). Liquid Torem Citrate is used to treat breast cancer in post-menopausal women. It does this by exerting estrogen antagonistic effects in certain tissue, most notably, breast tissue. This is actually the same mechanism of action found in Tamox. This is why tamox is often recommended to researchers who are trying to avoid gynecomastia. Liquid Torem Citrate has several other well known effects, which are not simply limited to preventing the abnormal growth of breast tissue. At the hypothalamus and pituitary, estrogen acts in cooperation with the male subject body’s negative feedback loop to send a signal to decrease the secretion of LHand FSH. When LH secretion is lowered, so are natural testosterone levels. Liquid Torem Citrate may even act as an estrogen antagonist in the hypothalamus and pituitary, which would also increase testosterone production. Because its androgenicity to estrogenicity ratio is 5x that of Liquid Tamoxe, Liquid Torem citrate is highly likely to be capable of increasing testosterone.
Toremifene is used to treat breast cancer that has spread to other parts of the body in women who have experienced menopause (‘change of life’; end of monthly menstrual periods). Toremifene is in a class of medications called nonsteroidal antiestrogens. It works by blocking the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow.
SERMs (Selective Estrogen Receptor Modulators) are best known to bind with estrogen receptors, blocking some estrogen actions while permitting others. They exhibit their actions differently in various tissues, therefore the “selective” descriptor. They selectively impede some while encouraging other estrogen-like actions. Nolvadex (tamoxifen citrate), Fareston (Toremifene) and Clomid (clomiphene citrate) are the three most commonly utilized SERMs. In men, all three of these drugs oppose the negative feedback of estrogens on the hypothalamus and encourage the release of Gonadotropin Releasing Hormone. Luteinizing Hormone (LH) production by the pituitary will be amplified as a result, which in turn can upsurge the making of endogenous testosterone. Although the end result is much the same between the three drugs, the methodology is quite different. Nolvadex appears to be intensely anti-estrogenic both at the hypothalamus and pituitary, while Clomid, although a potent anti-estrogen at the hypothalamus seems to display feeble action on the pituitary gland. Furthermore, Clomid stimulates the release of increased amounts of gonadotropin so that a sooner and greater release of follicle stimulating hormone (FSH) and luteinizing hormone (LH) occurs. This sequentially results in an increase in testosterone production. Toremifene is fast becoming a very common and popular anti-estrogen, and this is mainly owed to the fact that there have been some promising clinical trials demonstrating its capabilities. The beneficial effects of Toremifene doses on the HPTA and endogenous Testosterone production in males has been documented in clinical studies. As described in the introduction of this passage, this is the result of Toremifene’s antagonistic effects on the hypothalamus where it serves to bind to Estrogen receptors located on the hypothalamus. As a result, the hypothalamus is essentially tricked into thinking that there is a severe lack of Estrogen in circulation in the bloodstream, and responds by signaling the pituitary gland to increase the production of LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone).
***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The products are for research purposes only.***